



DAC  
✓  
LW

## PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8739

Seiichi SAITO

Appln. No.: 10/812,357

Group Art Unit: Not Yet Assigned

Confirmation No.: 4105

Examiner: Not Yet Assigned

Filed: March 30, 2004

For: RM2 ANTIGEN (B1,4-GALNAC-DISIALYL-LC) AS PROSTATE CANCER-  
ASSOCIATED ANTIGEN

**AMENDMENT AND REQUEST UNDER 37 C.F.R. § 1.48(a) TO CORRECT  
INVENTORSHIP IN NONPROVISIONAL APPLICATION, OTHER THAN A REISSUE  
APPLICATION, AFTER OATH OR DECLARATION HAS BEEN FILED, PURSUANT  
TO 35 U.S.C. § 116**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please correct the inventorship of the above-identified application by adding the name of  
Senitiroh HAKOMORI as co-inventor, thereby changing the inventorship from Seiichi SAITO to  
Senitiroh HAKOMORI and Seiichi SAITO.

### REMARKS

In accordance with 37 C.F.R. § 1.48(a), submitted herewith are the following:

1. A statement from the person being added as an inventor that the error in  
inventorship occurred without deceptive intent on his part;

AMENDMENT AND REQUEST  
TO CORRECT INVENTORSHIP  
U.S. Application No. 10/812,357

A8739

2. An oath or declaration by the actual inventors as required by 37 C.F.R. § 1.63 or as permitted by 37 C.F.R. §§ 1.42, 1.43, or 1.47 (two copies, each signed by one inventor);

3. Since an assignment has been executed by one or more of the original named inventors, the written consent of the assignee; and

4. The processing fee of \$130.00 as set forth in 37 C.F.R. § 1.17(i).

A check for the processing fee of \$130.00 is attached. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: December 21, 2004

  
Susan J. Mack  
Registration No. 30,951



**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: A8739

Seiichi SAITO

Appln. No.: 10/812,357

Group Art Unit: Not Yet Assigned

Confirmation No.: 4105

Examiner: Not Yet Assigned

Filed: March 30, 2004

For: RM2 ANTIGEN (B1,4-GALNAC-DISIALYL-LC) AS PROSTATE CANCER-  
ASSOCIATED ANTIGEN

**STATEMENT OF ADDED AND/OR DELETED INVENTORS IN SUPPORT OF  
REQUEST UNDER 37 C.F.R. § 1.48(a) TO CORRECT INVENTORSHIP IN  
NONPROVISIONAL APPLICATION, OTHER THAN A REISSUE APPLICATION,  
AFTER OATH OR DECLARATION HAS BEEN FILED**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

I, Senitiroh HAKOMORI, the inventor being added to the above-identified application,  
do hereby declare that an error occurred in naming the inventors of the above-identified  
application and that the error occurred without deceptive intent on my part.

Name of Added Inventor: Senitiroh HAKOMORI

Signature: 

Date: Oct 21, 2004



**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: A8739

Seiichi SAITO

Appln. No.: 10/812,357

Group Art Unit: Not Yet Assigned

Confirmation No.: 4105

Examiner: Not Yet Assigned

Filed: March 30, 2004

For: RM2 ANTIGEN (B1,4-GALNAC-DISIALYL-LC) AS PROSTATE CANCER-ASSOCIATED ANTIGEN

**CONSENT OF THE ASSIGNEE TO CORRECTION OF INVENTORSHIP IN  
ACCORDANCE WITH 37 C.F.R. § 1.48(a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The undersigned, a representative of Northern Advancement Center for Science & Technology (NOASTEC), represents that NOASTEC is the owner of the entire right, title and interest of Application No. 10/812,357, filed on March 30, 2004 for RM2 ANTIGEN (B1,4-GALNAC-DISIALYL-LC) AS PROSTATE CANCER-ASSOCIATED ANTIGEN by virtue of an Assignment from the current named inventor thereof executed on May 4, 2004, filed with the U.S. Patent and Trademark Office on August 2, 2004, a copy of which is attached hereto.

The undersigned hereby certifies that the above-mentioned Assignment has been reviewed and to the best of the undersigned's knowledge and belief, title is in the party who is seeking to take this action.

CONSENT OF ASSIGNEE TO  
CORRECTION OF INVENTORSHIP  
U.S.Application No.10/812,357

A8739

The undersigned(whose title is supplied below)is empowered to sign this consent statement on behalf of the assignee.

NOASTEC hereby consents to the correction of inventorship in connection with the above-identified application whereby the name of Senitiroh HAKOMORI is added as co-inventor.

Name: NOASTEC (Northern Advancement Center for Science & Technology)

Title: RM2 ANTIGEN(  $\beta$  1,4-GALNAC-DISIALYL-LC4) AS PROSTATE

CANCER-ASSOCIATED ANTIGEN

Representative of NOASTEC ; Seiichi Nakano

Signature: Seiichi Nakano

Date: October 20 ,2004

**DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)**

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**RM-1 ANTIGEN (β1,4-GALNAC-DISIALYL-LC4) AS PROSTATE CANCER-ASSOCIATED ANTIGEN**

☐ Application of which  
is attached hereto

OR

☒ was filed on March 30, 2004 as United States Application Number  
or PCT International Application Number 10/812,357  
(Confirmation No. \_\_\_\_\_, and was amended on  
\_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part application(s), material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

Prior Application Number(s)

Country

Filing Date

Priority Claimed  
Yes No☐☒

I hereby claim benefit under 35 United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)

Filing Date

I hereby claim benefit under 35 United States Code §120 of any United States application(s) or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)

U.S. or International Filing Date

Status


I hereby appoint all attorneys of **SUGHRUE MION, PLLC** who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

<b>NAME OF SOLE OR FIRST INVENTOR:</b>			
Given Name (first and middle [if any]) Senitiroh		Family Name or Surname HAKOMORI	
Inventor's Signature 		Date Oct 21, 2004	
Residence: City Mercer Island	State Washington	Country USA	Citizenship USA
Mailing Address: 2024 80 <sup>th</sup> Avenue SE			
City Mercer Island	State Washington	Zip 98040-2205	Country USA

<b>NAME OF SECOND INVENTOR:</b>			
Given Name (first and middle [if any]) Seiichi		Family Name or Surname SAITO	
Inventor's Signature		Date	
Residence: City Aoba-ku	State Sendai	Country Japan	Citizenship Japanese
Mailing Address: 18-12-601 Tachimachi			
City Aoba-ku	State Sendai	Zip 980-0822	Country Japan

**DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)**

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**RM2 ANTIGEN ( $\beta$ 1,4-GALNAC-DISIALYL-LC4) AS PROSTATE CANCER-ASSOCIATED ANTIGEN**

the application of which

☐ is attached hereto

OR

☒ was filed on March 30, 2004 as United States Application Number or PCT International Application Number 10/812,357 (Confirmation No. \_\_\_\_\_, and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part application(s), material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

Prior Application Number(s)

Country

Filing Date

Priority Claimed

Yes No

☐

☒

I hereby claim benefit under 35 United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)

Filing Date

I hereby claim benefit under 35 United States Code §120 of any United States application(s) or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)

U.S. or International Filing Date

Status

I hereby appoint all attorneys of **SUGHRUE MION, PLLC** who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



<b>NAME OF SOLE OR FIRST INVENTOR:</b>			
Given Name (first and middle [if any]) Senitiroh		Family Name or Surname HAKOMORI	
Inventor's Signature		Date	
Residence: City Mercer Island	State Washington	Country USA	Citizenship USA
Mailing Address: 2024 80 <sup>th</sup> Avenue SE			
City Mercer Island	State Washington	Zip 98040-2205	Country USA

<b>NAME OF SECOND INVENTOR:</b>			
Given Name (first and middle [if any]) Seiichi		Family Name or Surname SAITO	
Inventor's Signature <i>Seiichi Saito</i>		Date <i>Oct 18, 2004</i>	
Residence: City Aoba-ku	State Sendai	Country Japan	Citizenship Japanese
Mailing Address: 18-12-601 Tachimachi			
City Aoba-ku	State Sendai	Zip 980-0822	Country Japan

## Assignment

Whereas, I/We, Senitiroh HAKOMORI of 2024 80<sup>th</sup> Avenue, SE, Washington, D.C. 98040-205 hereinafter called assignor(s), have invented certain improvements in RM2 ANTIGEN (B1,4-GALNAC-DISIALYL-LC4) AS PROSTATE CANCER-ASSOCIATED ANTIGEN and executed an application for Letters Patent of the United States of America therefor on \_\_\_\_\_; and

Whereas, NORTHERN ADVANCEMENT CENTER FOR SCIENCE & TECHNOLOGY of Kita Bldg. N7, W2, Kita-ku, Sapporo, Hokkaido 060-0807, Japan (assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America and all countries foreign thereto, including rights of priority under the International Convention of Paris (1883) as amended, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we hereby agree that the assignee may apply for foreign Letters Patent on the invention and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States and foreign applications when called upon to do so by the assignee.

I/We hereby authorize and request our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, NW, Washington, DC 20037-3213 to insert here in parentheses (Application number 10/812,357 and Confirmation number 4105, filed March 30, 2004) the application number and filing date of said application when known.

Date: \_\_\_\_\_ Oct 21, 2004  
s/ Senitiroh HAKOMORI

Date: \_\_\_\_\_  
s/

Date: \_\_\_\_\_  
s/

Date: \_\_\_\_\_  
s/

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)